A
Ankit Hanmandlu
Researcher at University of Texas Health Science Center at Houston
Publications - 14
Citations - 179
Ankit Hanmandlu is an academic researcher from University of Texas Health Science Center at Houston. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 5, co-authored 6 publications receiving 108 citations. Previous affiliations of Ankit Hanmandlu include University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives
Scott D. Collum,Javier Amione-Guerra,Ana S. Cruz-Solbes,Amara DiFrancesco,Adriana M. Hernandez,Ankit Hanmandlu,Keith A. Youker,Ashrith Guha,Harry Karmouty-Quintana +8 more
TL;DR: The current understating of PH in IPF is focused on, the main mediators that have been shown to play a role in the development of the disease are revisited and the experimental models available to study PH associated with lung fibrosis are discussed.
Journal ArticleDOI
Inhibition of hyaluronan synthesis attenuates pulmonary hypertension associated with lung fibrosis.
Scott D. Collum,Ning Yuan Chen,Adriana M. Hernandez,Ankit Hanmandlu,Heather Sweeney,Tinne C.J. Mertens,Tingting Weng,Fayong Luo,Jose G. Molina,Jonathan Davies,Ian Horan,Nicholas W. Morrell,Javier Amione-Guerra,Odeaa Al-Jabbari,Keith A. Youker,Wenchao Sun,Jayakumar Rajadas,Paul L. Bollyky,Bindu Akkanti,S. Jyothula,Neeraj Sinha,Ashrith Guha,Harry Karmouty-Quintana +22 more
TL;DR: Group III pulmonary hypertension is a highly lethal and widespread lung disorder that is a common complication in idiopathic pulmonary fibrosis (IPF) where it is considered to be the single most significant predictor of mortality.
Journal ArticleDOI
Adenosine and hyaluronan promote lung fibrosis and pulmonary hypertension in combined pulmonary fibrosis and emphysema.
Scott D. Collum,Jose G. Molina,Ankit Hanmandlu,Weizhen Bi,Mesias Pedroza,Tinne C.J. Mertens,Nancy Wareing,Wang Wei,Cory Wilson,Wenchao Sun,Jayakumar Rajadas,Paul L. Bollyky,Kemly Philip,Dewei Ren,Rajarajan Amirthalingam Thandavarayan,Brian A. Bruckner,Yang Xia,Michael R. Blackburn,Harry Karmouty-Quintana +18 more
TL;DR: Fibrotic deposition and PH are inhibited by the FDA-approved drug hymecromone, suggesting hyaluronan synthesis inhibition as a potential therapy for CPFE and highlighting a novel mechanism through HAS3-positive macrophages.
Journal ArticleDOI
Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension.
Tinne C.J. Mertens,Ankit Hanmandlu,Ly Tu,Carole Phan,Scott D. Collum,Ning Yuan Chen,Tingting Weng,Jonathan Davies,Chen Liu,Holger K. Eltzschig,S. Jyothula,Keshava Rajagopal,Yang Xia,Ashrith Guha,Brian A. Bruckner,Michael R. Blackburn,Christophe Guignabert,Harry Karmouty-Quintana +17 more
TL;DR: ADORA2B-dependent increased levels of IL-6, hyaluronan and Tgm2 in PASMC are revealed, consistent with reduced levels in ADORA 2Bf/f- Taglncre mice exposed to HX-SU or BLM, and these studies point at ADORa2B as a therapeutic target to treat PH.
Journal ArticleDOI
Mechanisms of Pulmonary Hypertension in Acute Respiratory Distress Syndrome (ARDS)
TL;DR: In this paper, the authors summarized the known mechanisms that promote pulmonary hypertension in acute respiratory distress syndrome (ARDS) and addressed the implications of PH in the setting of coronavirus disease 2019 (COVID-19).